Revolution Medicines, Inc. Increase (Decrease) in Accounts Payable
Revolution Medicines, Inc. (RVMD) reported Increase (Decrease) in Accounts Payable of $21.89 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-05
- Revolution Medicines, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $5.03M, a 42.58% decline year-over-year.
- Revolution Medicines, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $16.86M.
- Revolution Medicines, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$10.50M, a 135.76% decline year-over-year.
- Revolution Medicines, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $19.55M.
- Revolution Medicines, Inc. increase (decrease) in accounts payable for fiscal 2025 was $9.54M.
- Revolution Medicines, Inc. increase (decrease) in accounts payable for fiscal 2024 was -$6.46M, a 119.91% decline from fiscal 2023.
- Revolution Medicines, Inc. increase (decrease) in accounts payable for fiscal 2023 was $32.47M, a 345.51% increase from fiscal 2022.
- Revolution Medicines, Inc. increase (decrease) in accounts payable for fiscal 2022 was $7.29M, a 225.50% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $21.89M 10-Q · filed 2026-08-05 | $11.39M derived: sum of 3 quarters · filed 2026-08-05 | $30.93M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $16.86M 10-Q · filed 2026-05-06 | $6.36M derived: sum of 2 quarters · filed 2026-05-06 | $25.90M derived: sum of 3 quarters · filed 2026-05-06 | $34.66M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$10.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $9.04M derived: sum of 2 quarters · filed 2026-02-25 | $17.80M derived: sum of 3 quarters · filed 2026-08-05 | $9.54M 10-K · filed 2026-02-25 |
| 2025-09-30 | $19.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $28.31M derived: sum of 2 quarters · filed 2026-08-05 | $20.04M 10-Q · filed 2025-11-05 | $49.40M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $8.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $491.00K 10-Q · filed 2026-08-05 | $29.85M derived: sum of 3 quarters · filed 2026-08-05 | $27.07M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$8.27M 10-Q · filed 2026-05-06 | $21.09M derived: sum of 2 quarters · filed 2026-05-06 | $18.30M derived: sum of 3 quarters · filed 2026-05-06 | $14.22M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $29.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $26.57M derived: sum of 2 quarters · filed 2026-02-25 | $22.50M derived: sum of 3 quarters · filed 2026-02-25 | -$6.46M 10-K · filed 2026-02-25 |
| 2024-09-30 | -$2.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$6.87M derived: sum of 2 quarters · filed 2025-11-05 | -$35.83M 10-Q · filed 2025-11-05 | -$11.52M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | -$4.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$33.04M 10-Q · filed 2025-08-06 | -$8.73M derived: sum of 3 quarters · filed 2026-02-25 | -$8.15M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | -$28.96M 10-Q · filed 2025-05-07 | -$4.66M derived: sum of 2 quarters · filed 2026-02-25 | -$4.08M derived: sum of 3 quarters · filed 2026-02-25 | $4.56M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $24.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $24.89M derived: sum of 2 quarters · filed 2026-02-25 | $33.52M derived: sum of 3 quarters · filed 2026-02-25 | $32.47M 10-K · filed 2026-02-25 |
| 2023-09-30 | $580.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $9.21M derived: sum of 2 quarters · filed 2024-11-06 | $8.16M 10-Q · filed 2024-11-06 | $6.66M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $8.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $7.58M 10-Q · filed 2024-08-07 | $6.08M derived: sum of 3 quarters · filed 2025-02-26 | $16.32M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | -$1.05M 10-Q · filed 2024-05-08 | -$2.56M derived: sum of 2 quarters · filed 2025-02-26 | $7.68M derived: sum of 3 quarters · filed 2025-02-26 | $6.73M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | -$1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $8.73M derived: sum of 2 quarters · filed 2025-02-26 | $7.78M derived: sum of 3 quarters · filed 2025-02-26 | $7.29M 10-K · filed 2025-02-26 |
| 2022-09-30 | $10.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $9.29M derived: sum of 2 quarters · filed 2023-11-06 | $8.79M 10-Q · filed 2023-11-06 | $11.37M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | -$952.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$1.44M 10-Q · filed 2023-08-08 | $1.13M derived: sum of 3 quarters · filed 2024-02-26 | $1.32M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | -$492.00K 10-Q · filed 2023-05-08 | $2.08M derived: sum of 2 quarters · filed 2024-02-26 | $2.27M derived: sum of 3 quarters · filed 2024-02-26 | $3.88M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $2.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $2.76M derived: sum of 2 quarters · filed 2024-02-26 | $4.37M derived: sum of 3 quarters · filed 2024-02-26 | $2.24M 10-K · filed 2024-02-26 |
| 2021-09-30 | $189.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $1.80M derived: sum of 2 quarters · filed 2022-11-07 | -$334.00K 10-Q · filed 2022-11-07 | $4.28M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $1.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$523.00K 10-Q · filed 2022-08-09 | $4.09M derived: sum of 3 quarters · filed 2023-02-27 | $723.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | -$2.13M 10-Q · filed 2022-05-09 | $2.48M derived: sum of 2 quarters · filed 2023-02-27 | -$885.00K derived: sum of 3 quarters · filed 2023-02-27 | $1.26M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $4.62M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $1.25M derived: sum of 2 quarters · filed 2023-02-27 | $3.39M derived: sum of 3 quarters · filed 2023-02-27 | $305.00K 10-K · filed 2023-02-27 |
| 2020-09-30 | -$3.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$1.23M derived: sum of 2 quarters · filed 2021-11-10 | -$4.31M 10-Q · filed 2021-11-10 | -$78.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $2.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$941.00K 10-Q · filed 2021-08-11 | $3.29M derived: sum of 3 quarters · filed 2022-02-28 | $2.82M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$3.08M 10-Q · filed 2021-05-10 | $1.15M derived: sum of 2 quarters · filed 2022-02-28 | $677.00K derived: sum of 3 quarters · filed 2022-02-28 | $1.98M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $4.23M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $3.76M derived: sum of 2 quarters · filed 2022-02-28 | $5.07M derived: sum of 3 quarters · filed 2022-02-28 | $5.26M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$472.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $834.00K derived: sum of 2 quarters · filed 2020-11-12 | $1.03M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $1.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $1.50M 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $197.00K 10-Q · filed 2020-05-14 | |||
| 2018-12-31 | $109.00K 10-K · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |